| Title: |
Aromatase Inhibitor-Induced Carpal Tunnel Syndrome Immunohistochemical Analysis and Clinical Evaluation: An Observational, Cross-Sectional, Case–Control Study |
| Authors: |
Molayem I.; Marcovici L. L.; Gradini R.; Mancini M.; Taccogna S.; Pagnotta A. |
| Contributors: |
Molayem, I.; Marcovici, L. L.; Gradini, R.; Mancini, M.; Taccogna, S.; Pagnotta, A. |
| Publisher Information: |
Multidisciplinary Digital Publishing Institute (MDPI) |
| Publication Year: |
2025 |
| Collection: |
Sapienza Università di Roma: CINECA IRIS |
| Subject Terms: |
aromatase inhibitor; breast cancer; carpal tunnel syndrome; estrogen; receptor |
| Description: |
Background/Objectives: Breast cancer was the leading cause of malignant tumors among women in 2022. About two-thirds of breast cancer cases are hormone-receptor-positive. In these patients, aromatase inhibitors are a mainstay of treatment, but associated musculoskeletal symptoms can negatively affect patient compliance. Aromatase-inhibitor-induced carpal tunnel syndrome represents one of the main causes of aromatase inhibitor discontinuation, with a non-compliance rate of up to 67%, potentially leading to increased cancer mortality. This study investigates estrogen receptor expression in aromatase-inhibitor-induced carpal tunnel syndrome tissues, in order to better define its etiopathogenesis and derive preventive or therapeutic measures that can improve aromatase inhibitor patient compliance. To our knowledge, there is no study on this subject in the literature. Methods: Between 2023 and 2024, we recruited 14 patients at the Jewish Hospital of Rome, including seven patients with aromatase-inhibitor-induced carpal tunnel syndrome (study group) and seven with postmenopausal idiopathic carpal tunnel syndrome (control group). Each patient was evaluated based on a clinical visit, a questionnaire, instrumental exams, and serum hormone dosages and were treated with open carpal tunnel release surgery, during which transverse carpal ligament and flexor tenosynovium samples were collected. For immunohistochemical experiments, sections were treated with anti-estrogen receptor α and anti-estrogen receptor β antibodies. Results: The immunohistochemical features in the study and control groups were similar, demonstrating that tissues affected by aromatase-inhibitor-induced carpal tunnel syndrome are targets of direct estrogen action and that estrogen deprivation is correlated with disease etiogenesis. Surgery was effective in patient treatment. Conclusions: Aromatase-inhibitor-induced carpal tunnel syndrome represents a newly defined form of the disease. This syndrome represents one of the main causes of aromatase inhibitor ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
volume:14; issue:15; journal:JOURNAL OF CLINICAL MEDICINE; https://hdl.handle.net/11573/1745907 |
| DOI: |
10.3390/jcm14155513 |
| Availability: |
https://hdl.handle.net/11573/1745907; https://doi.org/10.3390/jcm14155513 |
| Accession Number: |
edsbas.8C620B46 |
| Database: |
BASE |